ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0933

Advanced Multiparametric Magnetic Resonance Imaging of Muscle for Detection and Quantification of Muscle Disease in Systemic Sclerosis

Julie Paik1, Fredrick Wigley2, Laura Fayad3, Laura Hummers4 and Michael Jacobs1, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Joh, Baltimore, MD, 4Johns Hopkins Univerisity, Ellicott City, MD

Meeting: ACR Convergence 2020

Keywords: Imaging, Myopathies, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is underappreciated yet an important manifestation of SSc. While it has been reported that there are distinct histopathologic subsets of myopathy, Multiparametric muscle magnetic resonance imaging (mpMRI) patterns are unknown and the degree of involvement is yet quantified.  In order to determine whether unique mpMRI muscle tissue signatures exist in SSc associated myopathy, we implemented advanced mpMRI muscle techniques in the evaluation of SSc in patients with muscle weakness.

Methods: SSc patients were identified as having a skeletal myopathy as defined by proximal weakness and at least one abnormal diagnostic test such as muscle enzymes, EMG, MRI or muscle biopsy. Eligible SSc patients with a myopathy and age matched healthy controls were prospectively recruited. The mpMRI protocol consisted of anatomical and advanced functional sequences that included T1– and T2-weighted, T2 mapping, STIR, Dixon, and diffusion weighted images(DWI) and Apparent Diffusion Coefficient of Water (ADC) maps  for  detection and quantification the burden of muscle involvement in SSc associated myopathy.  MpMRI between muscle groups in each cohort were tested using a paired t-test and significance was set at p< 0.05.

Results: There were a total of 10 patients, seven who met the 2013 ACR/EULAR criteria for systemic sclerosis and three healthy controls, who underwent the research mpMRI.  Six of seven (86%) had diffuse cutaneous SSc. Four of the 7 patients had prior muscle biopsies and demonstrated muscle heterogeneity ranging from a fibrosing myopathy (n=1), necrotizing myopathy (n=2), and dermatomyositis (n=1).  Five of the seven were on at least 1 immunosuppressant and/or IVIG for the treatment of myopathy. Mean creatine kinase was 152 + 111 within 3 months of the mpMRI. There were significant differences between abnormal and normal obturator muscle groups (external and internal) using mpMRI T2 map values (p=0.02). (Internal Right Side:130±28 versus 87±16 msec and Left Side:138±23 versus 91±16 msec), (External Right Side:157±26 versus 87±16 msec and Left Side:155±26 versus 100±33 msec).  Similarly, the ADC values were significantly different in these muscle groups.  Figure 1 depicts a representative case where the white arrows show the increased signal intensity in the obturators on the STIR, T2 maps and ADC maps in a patient compared to a normal control.

Conclusion: In this preliminary study of SSc patients with skeletal myopathy, we demonstrated that by using advanced mpMRI, techniques, the obturator muscles of the pelvis were preferentially affected by SSc compared to healthy controls. Advanced muscle mpMRI could be a useful non-invasive imaging biomarker for muscle disease in SSc associated myopathy that provides new quantifiable metrics.

Representative cases of Multiparametric muscle MRI in a control and SSc patient


Disclosure: J. Paik, None; F. Wigley, None; L. Fayad, None; L. Hummers, Corbus Pharmaceuticals, 1, 2, Boehringer Ingelheim, 1, 2, CSL Behring, 1, 2, Cumberland Pharmaceuticals, 1, Medpace, 1, Glaxo Smith Kline, 1, Kadmon Corporation, 1; M. Jacobs, None.

To cite this abstract in AMA style:

Paik J, Wigley F, Fayad L, Hummers L, Jacobs M. Advanced Multiparametric Magnetic Resonance Imaging of Muscle for Detection and Quantification of Muscle Disease in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/advanced-multiparametric-magnetic-resonance-imaging-of-muscle-for-detection-and-quantification-of-muscle-disease-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/advanced-multiparametric-magnetic-resonance-imaging-of-muscle-for-detection-and-quantification-of-muscle-disease-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology